Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
44.05
-0.11 (-0.25%)
Feb 20, 2026, 11:51 AM EST - Market open
Exelixis Employees
Exelixis had 1,077 employees as of December 31, 2025. The number of employees decreased by 70 or -6.10% compared to the previous year.
Employees
1,077
Change (1Y)
-70
Growth (1Y)
-6.10%
Revenue / Employee
$2,154,249
Profits / Employee
$726,620
Market Cap
11.44B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,077 | -70 | -6.10% |
| Dec 31, 2024 | 1,147 | -163 | -12.44% |
| Dec 31, 2023 | 1,310 | 87 | 7.11% |
| Dec 31, 2022 | 1,223 | 269 | 28.20% |
| Dec 31, 2021 | 954 | 181 | 23.42% |
| Dec 31, 2020 | 773 | 156 | 25.28% |
| Dec 31, 2019 | 617 | 133 | 27.48% |
| Dec 31, 2018 | 484 | 112 | 30.11% |
| Dec 31, 2017 | 372 | 85 | 29.62% |
| Dec 31, 2016 | 287 | 172 | 149.57% |
| Dec 31, 2015 | 115 | 17 | 17.35% |
| Dec 31, 2014 | 98 | -129 | -56.83% |
| Dec 31, 2013 | 227 | 53 | 30.46% |
| Dec 31, 2012 | 174 | -26 | -13.00% |
| Dec 31, 2011 | 200 | -183 | -47.78% |
| Dec 31, 2010 | 383 | -293 | -43.34% |
| Dec 31, 2009 | 676 | 0 | - |
| Dec 31, 2008 | 676 | -59 | -8.03% |
| Dec 31, 2007 | 735 | 84 | 12.90% |
| Dec 31, 2006 | 651 | 101 | 18.36% |
| Dec 31, 2005 | 550 | 33 | 6.38% |
| Dec 31, 2004 | 517 | -56 | -9.77% |
| Dec 31, 2003 | 573 | 23 | 4.18% |
| Dec 31, 2002 | 550 | -21 | -3.68% |
| Dec 31, 2001 | 571 | 214 | 59.94% |
| Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| BioMarin Pharmaceutical | 3,040 |
| Jazz Pharmaceuticals | 2,800 |
| Ascendis Pharma | 1,189 |
| Ionis Pharmaceuticals | 1,069 |
| Axsome Therapeutics | 816 |
| Madrigal Pharmaceuticals | 528 |
| Avidity Biosciences | 391 |
EXEL News
- 9 days ago - Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 18 days ago - Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer - Business Wire
- 22 days ago - Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval - Seeking Alpha
- 23 days ago - Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 - Business Wire
- 4 weeks ago - Exelixis: High-Growth Oncology Name Trading At A Discount - Seeking Alpha
- 5 weeks ago - Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 - Business Wire